SNYNF (Sanofi) Short Interest

View and export this data going back to 2009. Start your Free Trial

What is Sanofi Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Sanofi's Short Interest

For the Drug Manufacturers - General subindustry, Sanofi's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Short Interest distribution charts can be found below:

* The bar in red indicates where Sanofi's Short Interest falls into.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (OTCPK:SNYNF) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

SNY:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.